Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Amortization of Deferred Charges (2019 - 2024)

Fennec Pharmaceuticals filings provide 6 years of Amortization of Deferred Charges readings, the most recent being -$1.1 million for Q4 2024.

  • On a quarterly basis, Amortization of Deferred Charges fell 2069.09% to -$1.1 million in Q4 2024 year-over-year; TTM through Dec 2024 was $21000.0, a 90.5% decrease, with the full-year FY2024 number at $21000.0, down 90.5% from a year prior.
  • Amortization of Deferred Charges hit -$1.1 million in Q4 2024 for Fennec Pharmaceuticals, down from $301000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $799000.0 in Q2 2024 to a low of -$1.1 million in Q4 2024.
  • Median Amortization of Deferred Charges over the past 5 years was $30000.0 (2020), compared with a mean of $48066.7.
  • Biggest five-year swings in Amortization of Deferred Charges: soared 1988.24% in 2020 and later plummeted 2069.09% in 2024.
  • Fennec Pharmaceuticals' Amortization of Deferred Charges stood at $355000.0 in 2020, then plummeted by 97.75% to $8000.0 in 2021, then surged by 587.5% to $55000.0 in 2022, then changed by 0.0% to $55000.0 in 2023, then plummeted by 2069.09% to -$1.1 million in 2024.
  • The last three reported values for Amortization of Deferred Charges were -$1.1 million (Q4 2024), $301000.0 (Q3 2024), and $799000.0 (Q2 2024) per Business Quant data.